Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients
Open accessThe DOI matches its Crossref record; 31 of the 34 references it cites were found in a registry or an index.
Abstract
OBJECTIVE Monogenic diabetes, a young-onset form of diabetes, is often misdiagnosed as type 1 diabetes, resulting in unnecessary treatment with insulin. A screening approach for monogenic diabetes is needed to accurately select suitable patients for expensive diagnostic genetic testing. We used C-peptide and islet autoantibodies, highly sensitive and specific biomarkers for discriminating type 1 from non–type 1 diabetes, in a biomarker screening pathway for monogenic diabetes. RESEARCH DESIGN AND METHODS We studied patients diagnosed at age 30 years or younger, currently younger than 50 years, in two U.K. regions with existing high detection of monogenic diabetes. The biomarker screening pathway comprised three stages: 1) assessment of endogenous insulin secretion using urinary C-peptide/creatinine ratio (UCPCR); 2) if UCPCR was ≥0.2 nmol/mmol, measurement of GAD and IA2 islet autoantibodies; and 3) if negative for both autoantibodies, molecular genetic diagnostic testing for 35 monogenic diabetes subtypes. RESULTS A total of 1,407 patients participated (1,365 with no known genetic cause, 34 with monogenic diabetes, and 8 with cystic fibrosis–related diabetes). A total of 386 out of 1,365 (28%) patients had a UCPCR ≥0.2 nmol/mmol, and 216 out of 386 (56%) were negative for GAD and IA2 and underwent molecular genetic testing. Seventeen new cases of monogenic diabetes were diagnosed (8 common Maturity Onset Diabetes of the Young [Sanger sequencing] and 9 rarer causes [next-generation sequencing]) in addition to the 34 known cases (estimated prevalence of 3.6% [51/1,407] [95% CI 2.7–4.7%]). The positive predictive value was 20%, suggesting a 1-in-5 detection rate for the pathway. The negative predictive value was 99.9%. CONCLUSIONS The biomarker screening pathway for monogenic diabetes is an effective, cheap, and easily implemented approach to systematically screening all young-onset patients. The minimum prevalence of monogenic diabetes is 3.6% of patients diagnosed at age 30 years or younger.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Monogenic diabetes is found in approximately 4% of those diagnosed with diabetes before the age of 30 years; the likelihood of monogenic diabetes rises to 20% where islet antibodies are negative and C-peptide secretion is maintained (18).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A biomarker screening pathway, such as the combination of urinary C-peptide/creatinine ratio and antibody screening, may aid in determining who should get genetic testing for MODY (171).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [171]
The cited source says what the claim attributes to it.
In the citing paper
“Monogenic diabetes is found in approximately 4% of those diagnosed with diabetes before the age of 30 years; the likelihood of monogenic diabetes rises to 20% where islet antibodies are negative and C-peptide secretion is maintained (18).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Problems of Spectrum and Bias in Evaluating the Efficacy of Diagnostic Tests
Ransohoff, D. F., & Feinstein, A. R. (1978) · New England Journal of Medicine · doi:10.1056/nejm197810262991705 · Cited by 1,734
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
Pearson, E. R., Flechtner, I., Njølstad, P. R., Malecki, M. T., Flanagan, S. E., Larkin, B., Ashcroft, F. M., Klimes, I., Codner, E., Iotova, V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061759 · Cited by 988
Self-citationMaturity-onset diabetes of the young (MODY): how many cases are we missing?
Shields, B. M., Hicks, S., Shepherd, M. H., Colclough, K., Hattersley, A. T., & Ellard, S. (2010) · Diabetologia · doi:10.1007/s00125-010-1799-4 · Cited by 725 · cited 1×
“referrals data [3]), and there is on average a delay of 13 years from diabetes diagnosis to a confirmed genetic diagnosis (16), it is crucial to study adults as well.”
Self-citationThe clinical utility of C‐peptide measurement in the care of patients with diabetes
Jones, A. G., & Hattersley, A. T. (2013) · Diabetic Medicine · doi:10.1111/dme.12159 · Cited by 628
Self-citationGenetic cause of hyperglycaemia and response to treatment in diabetes
Pearson, E. R., Starkey, B. J., Powell, R. J., Gribble, F. M., Clark, P. M., & Hattersley, A. T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14571-0 · Cited by 607
Self-citationPihoker, C., Gilliam, L. K., Ellard, S., Dabelea, D., Davis, C., Dolan, L. M., Greenbaum, C. J., Imperatore, G., Lawrence, J. M., Marcovina, S. M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1279 · Cited by 397
Self-citationShields, B. M., McDonald, T. J., Ellard, S., Campbell, M. J., Hyde, C., & Hattersley, A. T. (2012) · Diabetologia · doi:10.1007/s00125-011-2418-8 · Cited by 335 · cited 1×
“Statistical Analysis For comparing new cases diagnosed through the screening pathway to known cases of monogenic diabetes and for comparing the biomarker screening pathway with an approach using clinical features (including the MODY probability calculator [9]) to detect monogenic diabetes, variables were categorical,…”
Self-citationBasic Issues in Population Screening for Cancer 23
(1980) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/64.5.1263 · Cited by 321
Improved genetic testing for monogenic diabetes using targeted next-generation sequencing
Ellard, S., Lango Allen, H., De Franco, E., Flanagan, S. E., Hysenaj, G., Colclough, K., Houghton, J. A. L., Shepherd, M., Hattersley, A. T., Weedon, M. N., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-2962-5 · Cited by 307
Self-citationClinical Applications of Diabetes Antibody Testing
Bingley, P. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1365 · Cited by 278
Research works printed but not linked: 1
- Cole, 1980, Basic issues in population screening for cancer, J Natl Cancer Inst, 64, 1263
Cited by
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s002 · Cited by 3,116
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
2. Classification and Diagnosis of Diabetes:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s002 · Cited by 2,433
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s002 · Cited by 2,086
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
“Differentiating Type 1 Diabetes From Monogenic Diabetes Monogenic diabetes is found in approximately 4% of those diagnosed with diabetes before the age of 30 years; the likelihood of monogenic diabetes rises to 20% where islet antibodies are negative and C-peptide secretion is maintained (18).”
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05568-3 · Cited by 378
“Monogenic diabetes is found in approximately 4% of those diagnosed with diabetes before the age of 30 years; the likelihood of monogenic diabetes rises to 20% where islet antibodies are negative and C-peptide secretion is maintained [18].”
Type 2 diabetes: a multifaceted disease
Pearson, E. R. (2019) · Diabetologia · doi:10.1007/s00125-019-4909-y · Cited by 257
Self-citationThe clinical consequences of heterogeneity within and between different diabetes types
Redondo, M. J., Hagopian, W. A., Oram, R., Steck, A. K., Vehik, K., Weedon, M., Balasubramanyam, A., & Dabelea, D. (2020) · Diabetologia · doi:10.1007/s00125-020-05211-7 · Cited by 190
Rodacki, M., Teles, M. G., Gabbay, M. A. L., Montenegro, R. M., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-1 · Cited by 194
De Franco, E., Saint‐Martin, C., Brusgaard, K., Knight Johnson, A. E., Aguilar‐Bryan, L., Bowman, P., Arnoux, J., Larsen, A. R., Sanyoura, M., Greeley, S. A. W., et al. (2020) · Human Mutation · doi:10.1002/humu.23995 · Cited by 174
“Current estimates suggest that approxi- mately 0.4% of all diabetes (and up to 3.5% of those diagnosed under 30 years of age) has a monogenic cause (Shepherd et al., 2016; Shields et al., 2017).”
BackgroundInfluentialSelf-citationBonnefond, A., Unnikrishnan, R., Doria, A., Vaxillaire, M., Kulkarni, R., Mohan, V., Trischitta, V., & Froguel, P. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00421-w · Cited by 188
Pancreatic β-cell tRNA hypomethylation and fragmentation link TRMT10A deficiency with diabetes
Cosentino, C., Toivonen, S., Diaz Villamil, E., Atta, M., Ravanat, J.-L., Demine, S., Schiavo, A. A., Pachera, N., Deglasse, J.-P., Jonas, J.-C., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky839 · Cited by 137
Self-citationShields, B. M., McDonald, T. J., Oram, R., Hill, A., Hudson, M., Leete, P., Pearson, E. R., Richardson, S. J., Morgan, N. G., Hattersley, A. T., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0465 · Cited by 120
Self-citationRiddle, M. C., Philipson, L. H., Rich, S. S., Carlsson, A., Franks, P. W., Greeley, S. A. W., Nolan, J. J., Pearson, E. R., Zeitler, P. S., & Hattersley, A. T. (2020) · Diabetes Care · doi:10.2337/dci20-0065 · Cited by 117
Self-citationstudy, F. T. U., Shepherd, M. H., Shields, B. M., Hudson, M., Pearson, E. R., Hyde, C., Ellard, S., Hattersley, A. T., & Patel, K. A. (2018) · Diabetologia · doi:10.1007/s00125-018-4728-6 · Cited by 109
Self-citationPhenotypic and genetic classification of diabetes
Deutsch, A. J., Ahlqvist, E., & Udler, M. S. (2022) · Diabetologia · doi:10.1007/s00125-022-05769-4 · Cited by 108
“4% of all diabetes [34] and 1–6% of paediatric diabetes cases [35].”
BackgroundColclough, K., Ellard, S., Hattersley, A. T., & Patel, K. (2021) · Diabetes · doi:10.2337/db21-0517 · Cited by 89
“…for clinicians to have detailed knowledge of all monogenic diabetes syndromes and focuses on identifying patients with a clinical suspicion of monogenic diabetes using tools that are independent of aetiology (e.g. C-peptide, islet auto-antibodies and type 1 diabetes genetic risk score) (3; 22).”
Self-citationGenetics of Monogenic Diabetes: Present Clinical Challenges
Misra, S., & Owen, K. R. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1111-4 · Cited by 83
Lynam, A., McDonald, T., Hill, A., Dennis, J., Oram, R., Pearson, E., Weedon, M., Hattersley, A., Owen, K., Shields, B., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031586 · Cited by 72
Self-citationShields, B. M., Dennis, J., Angwin, C. D., Warren, F. C., Henley, W., Farmer, A. A., Sattar, N. A., Holman, R. R., Jones, A. G., Pearson, E. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02120-7 · Cited by 76
“…between metformin and gliclazide treatment for patients with HNF1A_MODY 15 ), the overall improvement through stratification would likely have a pronounced effect at the population level, as type 2 diabetes is far more common (90% of all diabetes for type 2 compared to 1% for MODY) 16,17 .”
Self-citationGibb, F. W., McKnight, J. A., Clarke, C., & Strachan, M. W. J. (2020) · Diabetologia · doi:10.1007/s00125-020-05099-3 · Cited by 74
on behalf of the Monogenic Diabetes Study Group of the Société Francophone du Diabète, Donath, X., Saint‐Martin, C., Dubois‐Laforgue, D., Rajasingham, R., Mifsud, F., Ciangura, C., Timsit, J., & Bellanné‐Chantelot, C. (2019) · BMC Medicine · doi:10.1186/s12916-019-1363-0 · Cited by 71
Foteinopoulou, E., Clarke, C. A. L., Pattenden, R. J., Ritchie, S. A., McMurray, E. M., Reynolds, R. M., Arunagirinathan, G., Gibb, F. W., McKnight, J. A., & Strachan, M. W. J. (2021) · Diabetic Medicine · doi:10.1111/dme.14449 · Cited by 61
Mutations and variants of ONECUT1 in diabetes
Philippi, A., Heller, S., Costa, I. G., Senée, V., Breunig, M., Li, Z., Kwon, G., Russell, R., Illing, A., Lin, Q., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01502-7 · Cited by 59
The use of precision diagnostics for monogenic diabetes: a systematic review and expert opinion
Murphy, R., Colclough, K., Pollin, T. I., Iklé, J. M., Svalastoga, P., Maloney, K. A., Saint‐Martin, C., Molnes, J., PMDI, A., Tobias, D. K., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00369-8 · Cited by 58
Self-citationDiagnosis and management of glucokinase monogenic diabetes in pregnancy: current perspectives
Rudland, V. L. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s186610 · Cited by 58
“25,26 Genetic testing of the GCK gene involves sequencing the promoter, exons 1a, 2 – 10 and splice sites of the GCK gene.”
BackgroundPang, L., Colclough, K., Shepherd, M. H., McLean, J., Pearson, E. R., Ellard, S., Hattersley, A. T., & Shields, B. M. (2022) · Diabetes Care · doi:10.2337/dc21-2056 · Cited by 55
Self-citationJuszczak, A., Štambuk, T., Vučković, F., Bennett, A. J., Shah, N., Medvidović, E. P., Groves, C. J., Šekerija, M., Chandler, K. A., Burrows, C., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0422 · Cited by 52
DNAJC3 deficiency induces β-cell mitochondrial apoptosis and causes syndromic young-onset diabetes
Lytrivi, M., Senée, V., Salpea, P., Fantuzzi, F., Philippi, A., Abdulkarim, B., Sawatani, T., Marín‐Cañas, S., Pachera, N., Degavre, A., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-0636 · Cited by 54
Maturity Onset Diabetes of the Young—New Approaches for Disease Modelling
Skoczek, D., Dulak, J., & Kachamakova‐Trojanowska, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147553 · Cited by 48
“In two recent population studies, it was suggested that screening for monogenic biomarkers (endogenous insulin secretion, the ratio of urinary C-peptide and creatinine (UCPCR), islet autoantibodies), is an effective, cheap and easily implemented approach for systematic screening of young patients [122,123].”
BackgroundHow do I diagnose Maturity Onset Diabetes of the Young in my patients?
Colclough, K., & Patel, K. (2022) · Clinical Endocrinology · doi:10.1111/cen.14744 · Cited by 46
“In patients diagnosed under the age of 30 years, testing patients with negative antibodies and detectable C‐peptide identifies MODY in one in five patients tested.(40) If necessary, specificity can be improved by testing only those patients with a parent affected with diabetes, and/or those with less severe hyperglyca…”
BackgroundSelf-citationHuerta‐Chagoya, A., Schroeder, P. H., Mandla, R., Li, J., Morris, L., Vora, M., Alkanaq, A. N., Nagy, D., Szczerbiński, Ł., Madsen, J. G. S., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01947-9 · Cited by 51
Li, M., Wang, S., Xu, K., Chen, Y., Fu, Q., Gu, Y., Shi, Y., Zhang, M., Sun, M., Chen, H., et al. (2019) · Diabetes · doi:10.2337/db19-0510 · Cited by 41
Not quite type 1 or type 2, what now? Review of monogenic, mitochondrial, and syndromic diabetes
Yeung, R. O., Hannah‐Shmouni, F., Niederhoffer, K. Y., & Walker, M. A. (2018) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-018-9446-3 · Cited by 41
Ellard, S., Colclough, K., Patel, K. A., & Hattersley, A. T. (2019) · Journal of Clinical Investigation · doi:10.1172/jci133516 · Cited by 38
Self-citationTimsit, J., Ciangura, C., Dubois‐Laforgue, D., Saint‐Martin, C., & Bellanné‐Chantelot, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.802423 · Cited by 38
“Outside the Pregnancy, the Diagnosis of GCK-MODY May Be Raised on the Discovery of Hyperglycemia In young and lean individuals, type 1 diabetes should be excluded by the absence of diabetes-related autoantibodies (59).”
BackgroundChallenges in the diagnosis of diabetes type in pediatrics
Siller, A. F., Tosur, M., Relan, S., Astudillo, M., McKay, S. V., Dabelea, D., & REDONDO, M. J. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13070 · Cited by 37
A classification and regression tree analysis identifies subgroups of childhood type 1 diabetes
Achenbach, P., Hippich, M., Zapardiel‐Gonzalo, J., Karges, B., Holl, R. W., Petrera, A., Bonifacio, E. E., & Ziegler, A. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104118 · Cited by 38
Monogenic diabetes in adults: what are the new developments?
Owen, K. R. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.04.006 · Cited by 34
Oliveira, S. C., Neves, J. S., Pérez, A., & Carvalho, D. M. (2019) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2019.07.012 · Cited by 37
“When matched with traditional criteria, the prediction model improved the sensitivity and specificity for identifying MODY.”
BackgroundInfluentialREDONDO, M. J., & Balasubramanyam, A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab545 · Cited by 33
Genetics Coming of Age in Type 1 Diabetes
Cerolsaletti, K., Hao, W., & Greenbaum, C. J. (2019) · Diabetes Care · doi:10.2337/dci18-0039 · Cited by 39
Patel, K., Weedon, M. N., Shields, B. M., Pearson, E. R., Hattersley, A. T., & McDonald, T. J. (2018) · Diabetes Care · doi:10.2337/dc18-0373 · Cited by 26
Self-citationHidden MODY—Looking for a Needle in a Haystack
Urbanová, J., Brunerová, L., & Brož, J. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00355 · Cited by 27
“Since strict adherence to traditional clinical criteria is insufficient in identifying MODY patients, other algorithms (10, 23, 26, 38), predictive models (11) or selected biomarkers (39) have been tested.”
BackgroundFuture Roadmaps for Precision Medicine Applied to Diabetes: Rising to the Challenge of Heterogeneity
Bowman, P., Flanagan, S. E., & Hattersley, A. T. (2018) · Journal of Diabetes Research · doi:10.1155/2018/3061620 · Cited by 28
“6% of all cases diagnosed under 30 years [3].”
BackgroundSelf-citationReilly, F. H., Sánchez-Lechuga, B., Clinton, S. K., Crowe, G.-G., Burke, M., Ng, N., Colclough, K., & Byrne, M. M. (2019) · Diabetic Medicine · doi:10.1111/dme.14145 · Cited by 25
Self-citationVaxillaire, M., Froguel, P., & Bonnefond, A. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1202-x · Cited by 24
Santos, T., Fonseca, L., Monteiro, S. S., Duarte, D. B., Lopes, A., Carvalho, A., Oliveira, M. J., Borges, T., Laranjeira, F., Couce, M. L., et al. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.332 · Cited by 28
Economics of Genetic Testing for Diabetes
Naylor, R. N. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1140-7 · Cited by 25
Type of diabetes mellitus: Does it matter to the clinician?
Hoogwerf, B. J. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.19020 · Cited by 28
Bazzazzadehgan, S., Shariat‐Madar, Z., & Mahdi, F. (2025) · Biomolecules · doi:10.3390/biom15030414 · Cited by 21
Maturity-Onset Diabetes of the Young (MODY) in Portugal: Novel GCK, HNFA1 and HNFA4 Mutations
Alvelos, M. I., Gonçalves, C. I., Coutinho, E., Almeida, J. T., Bastos, M., Sampaio, M. L. V., Melo, M., Martins, S. A., Dinis, I., Mirante, A., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010288 · Cited by 21
Update on Monogenic Diabetes in Korea
Yang, Y., Kwak, S. H., & Park, K. S. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0214 · Cited by 19
“Features atypical for T1DM are as follows [54]: absence of pancreatic islet autoantibodies [55], measurable Cpeptide in the presence of hyperglycemia [56,57], low insulin requirement for treatment and lack of diabetic ketoacidosis.”
BackgroundBOWDEN, T. L., Letourneau, L. R., Kandasamy, B., Sanyoura, M., Tian, P., Harris, A. G., Bell, G. I., Philipson, L. H., Naylor, R. N., & Greeley, S. A. W. (2021) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2021.735548 · Cited by 20
“5% of all diabetes cases diagnosed before age 30 and there are currently over 30 known genes associated with monogenic diabetes (1-4).”
BackgroundMonogenic Diabetes: Genetics and Relevance on Diabetes Mellitus Personalized Medicine
Sousa, M., & Bruges‐Armas, J. (2019) · Current Diabetes Reviews · doi:10.2174/1573399816666191230114352 · Cited by 19
The Diabetes Study Group of the Italian Society of Pediatric Endocrinology and Diabetes (ISPED), Delvecchio, M., Salzano, G., Bonura, C., Cauvin, V., Cherubini, V., d’Annunzio, G., Franzese, A., Giglio, S., Grasso, V., et al. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1179-y · Cited by 18
Case 6-2020: A 34-Year-Old Woman with Hyperglycemia
Udler, M. S., Powe, C. E., & Austin-Tse, C. A. (2020) · New England Journal of Medicine · doi:10.1056/nejmcpc1913475 · Cited by 17
Yaghootkar, H., Abbasi, F., Ghaemi, N., Rabbani, A., Wakeling, M. N., Eshraghi, P., Enayati, S., Vakili, S., Heidari, S., Patel, K., et al. (2019) · Diabetic Medicine · doi:10.1111/dme.14071 · Cited by 19
Self-citationMifsud, F., Saint‐Martin, C., Dubois‐Laforgue, D., Bouvet, D., Timsit, J., & Bellanné‐Chantelot, C. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109908 · Cited by 19
Chan, J. C. N., Chow, E., Kong, A. P. S., Cheung, E. Y. N., Tony, O., Lim, C. K. P., Fan, B., Tsoi, S. T. F., Fan, Y., Shi, M., et al. (2024) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2023.36 · Cited by 18
Campbell, M. R. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1730179 · Cited by 15
“If indicated by the results of the aforementioned tests, molecular analyses could follow [5].”
BackgroundInfluentialPopulation Prevalence, Penetrance, and Mortality for Genetically Confirmed MODY
Sharp, L. N., Colclough, K., Leech, J. M., Cannon, S. J., Laver, T. W., Hattersley, A. T., Weedon, M. N., & Patel, K. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf599 · Cited by 16
Self-citationZinc transporter 8 autoantibody testing requires age-related cut-offs
Grace, S. L., Cooper, A., Jones, A. G., & McDonald, T. J. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002296 · Cited by 15
Self-citationZhang, H., Kleinberger, J. W., Maloney, K. A., Guan, Y., Mathias, T. J., Bisordi, K., Streeten, E. A., Blessing, K. K., Snyder, M. N., Bromberger, L. A., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1975 · Cited by 13
Liu, Y., Xie, Z., Sun, X., Wang, Y., Xiao, Y., Luo, S., Huang, G., Li, X., Xia, Y., & Zhou, Z. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3381 · Cited by 13
“Thus, the cut-off age was set at 30 as is suggested by Park et al and Shields et al.26,27 The age at the onset of diabetes was inquired during the first visit of each patient.”
MethodStrategies to identify individuals with monogenic diabetes: results of an economic evaluation
Peters, J., Anderson, R., Shields, B. M., King, S., Hudson, M., Shepherd, M. H., McDonald, T. J., Pearson, E. R., Hattersley, A. T., & Hyde, C. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-034716 · Cited by 12
Self-citationMaturity onset diabetes of the young and beyond: the changing face of single-gene diabetes
Laver, T., & Patel, K. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf172 · Cited by 9
George, M. N., Leavens, K. F., & Gadue, P. J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.682625 · Cited by 11
“Many forms of monogenic diabetes have been recognized for decades and more gene causes are likely to be found in the upcoming years with the increasing use of exome and genome sequencing (17, 18).”
BackgroundGaál, Z., Szücs, Z., Kántor, I., Luczay, A., Tóth‐Heyn, P., Benn, O., Felszeghy, E., Karádi, Z., Madar, L., & Balogh, I. (2021) · Life · doi:10.3390/life11080771 · Cited by 11
“MODY Prevalence The estimated MODY prevalence is around 1–5% of all diabetes mellitus cases, but it varies depending on the population studied [12,13].”
BackgroundTsoi, S. T. F., Lim, C. K. P., Ronald, C. W., Lau, E. S. H., Fan, B., Chow, E., Kong, A. P. S., Chan, J. C. N., & Luk, A. O. Y. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3823 · Cited by 11
“23 On the other hand, the prevalence rate for patients diagnosed in youth at age 20 years in the present study appeared to be higher than that recorded in the Progress in Diabetes Genetics in Youth (ProDiGY) cohort of 3333 multi ‐ ethnic youths with type 2 diabetes in the United States (U.”
Sriram, A., Wakeling, M. N., Hattersley, A. T., Weedon, M. N., Colclough, K., Laver, T. W., & Patel, K. (2025) · Diabetes · doi:10.2337/db25-0442 · Cited by 13
“MODY is the most common form of monogenic diabetes, responsible for ~3% of all diabetes diagnosed under 30 years old (1).”
Self-citationSGLT2i as a Useful Adjunctive Medication for HNF4A-MODY
Suzuki, S., Kokumai, T., Furuya, A., & Takahashi, S. (2023) · Diabetes Care · doi:10.2337/dc22-1573 · Cited by 12
Identification of Ala2Thr mutation in insulin gene from a Chinese MODY10 family
Zhang, J., Liu, Y., Li, M., Ge, X., Wang, Y., Huang, X., Yang, D., Zhang, R., Chen, Y., Lü, M., et al. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03748-0 · Cited by 10
“A recent population study demonstrated that 3% of diabetes diagnosed under 30 in the UK was due to MODY [2].”
BackgroundUnmasking the Therapeutic Potential of Biomarkers in Type-1 Diabetes Mellitus
(2021) · Biointerface Research in Applied Chemistry · doi:10.33263/briac115.1318713201 · Cited by 11
Strakova, V., Elblová, L., Johnson, M. B., Dušátková, P., Obermannová, B., Petruželková, L., Koloušková, S., Šnajderová, M., Froňková, E., Svatoň, M., et al. (2019) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2019-0261 · Cited by 12
Self-citationHow can maturity-onset diabetes of the young be identified among more common diabetes subtypes?
Urbanová, J., Brunerová, L., & Brož, J. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-01543-6 · Cited by 9
Treatment of Diabetes Mellitus in Children and Adolescents
Yau, M., & Sperling, M. A. (2021) · Cited by 12
A ONECUT1 regulatory, non-coding region in pancreatic development and diabetes
Merz, S. K., Senée, V., Philippi, A., Oswald, F., Shaigan, M., Führer, M., Drewes, C., Allgöwer, C., Öllinger, R., Heni, M., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114853 · Cited by 10
An update on the diagnosis and management of monogenic diabetes
Colclough, K., van Heugten, R., & Patel, K. (2022) · Practical Diabetes · doi:10.1002/pdi.2410 · Cited by 8
Self-citationSteenkamp, D. W., Cheney, M. C., Ju, Z., Rodbard, D., & Wolpert, H. A. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad038 · Cited by 7
“Several programs to improve detection, based on application of clinical phenotype-based MODY risk predictors and enhanced genetic testing, have been implemented [10, 13-15].”
MethodMaloney, K. A., Mizerik, E. A., King, R. H., McGinnis, E. M., Perkowitz, S., Diamonstein, C. J., Schmanski, A. A., Saliganan, S., Shipper, A. G., Udler, M. S., et al. (2023) · Journal of Genetic Counseling · doi:10.1002/jgc4.1744 · Cited by 7
“…and T2D are polygenic, monogenic subtypes of diabetes (a subset of the third ADA category) exist and account for at least 0.4% of all diabetes, or over 150,000 cases in the United States and several million worldwide, and over 3% of young onset diabetes (Naylor et al., 2020; Shields et al., 2017).”
BackgroundInfluentialChristensen, A. S., Storgaard, H., Hædersdal, S., Hansen, T. F., Knop, F. K., & Vilsbøll, T. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-022517 · Cited by 7
Liu, W., Huang, X., Zhang, X., Cai, X., Han, X., Zhou, X., Chen, L., Zhang, R., Gong, S., Wang, Y., et al. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s229675 · Cited by 7
Arslanian, S. A., ghormli, L. K. E., Haymond, M., Chan, C. L., Chernausek, S. D., Gandica, R., Gubitosi‐Klug, R., Levitsky, L. L., Siska, M., Willi, S. M., et al. (2020) · Pediatric Diabetes · doi:10.1111/pedi.12998 · Cited by 7
Pediatric Monogenic Diabetes: A Unique Challenge and Opportunity
Harris, A. G., & Naylor, R. N. (2019) · Pediatric Annals · doi:10.3928/19382359-20190730-02 · Cited by 8
The evolution of C-peptide's role in diabetes care
Briggs, L., Read, A., Darch, S. J., Williams, E. L., Loh, W. J., & Kenkre, J. S. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000947 · Cited by 6
Rapid Point-of-Care Test for Determination of C-Peptide Levels
Rao, P. V., Bean, E., Nair-Schaef, D., Chen, S., Kazmierczak, S. C., Roberts, C. T., & Nagalla, S. R. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296821995557 · Cited by 6
Co-segregation analysis and functional trial in vivo of candidate genes for monogenic diabetes
Stankutė, I., Kazlauskienė, M., Blouin, J., Schwitzgebel, V., & Verkauskienė, R. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003038 · Cited by 6
The Etiological Diagnosis of Diabetes: Still a Challenge for the Clinician
Dubois‐Laforgue, D., & Timsit, J. (2023) · Endocrines · doi:10.3390/endocrines4020033 · Cited by 8
“In this context, the main differential diagnosis is T1D, and a MgD has been found in 4–15% of patients with no antibodies, or no antibodies and detectable insulin secretion [83,84,113,114].”
BackgroundThe Need to Increase Clinical Skills and Change the Genetic Testing Strategy for Monogenic Diabetes
Paola, R. D., Marucci, A., & Trischitta, V. (2022) · Diabetes · doi:10.2337/dbi21-0037 · Cited by 6
Oliveira, S. C., Neves, J. S., Pérez, A., & Carvalho, D. M. (2020) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2020.03.001 · Cited by 7
Pappachan, J. M., Sunil, B., Fernandez, C. J., Lahart, I. M., & Ashraf, A. P. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.2 · Cited by 6
“…97 >0.2 97.0 96.0 N/A N/A Wang et al, 2019, China22 23 >0.2 87.0 92.7 83.3 94.6 Positive T1DM by antibody tests and exclusion of MODY by genetic testing Shields et al, 2017, UK27 1,362 <0.2 N/A N/A N/A N/A Shepherd et al, 2016, UK28 817 <0.2 N/A N/A N/A N/A Yılmaz Ağladioğlu et al, 2015, Turkey26…”
BackgroundInfluentialUsing Data to Improve the Management of Diabetes: The Tayside Experience
Siddiqui, M. K., Hall, C., Cunningham, S. G., McCrimmon, R. J., Morris, A. D., Leese, G., & Pearson, E. R. (2022) · Diabetes Care · doi:10.2337/dci22-0003 · Cited by 7
“We showed that of 1365 patients, 386 had measurable insulin secretion; of these 216 were pancreatic autoantibody negative; of these 17 had monogenic diabetes (13).”
BackgroundMethodSelf-citationHohendorff, J., Zapała, B., Ludwig‐Słomczyńska, A. H., Solecka, I., Ucieklak, D., Matejko, B., Mrozińska, S., Malecki, M. T., & Szopa, M. (2020) · Minerva Medica · doi:10.23736/s0026-4806.19.06053-1 · Cited by 6
Liu, W. Y., Ma, Y., Cai, X., Zhu, Y. M., Zhang, M., Li, J., Chen, J., Shi, D., & Ji, L. (2022) · Endocrine Connections · doi:10.1530/ec-22-0244 · Cited by 7
Cardoso, P., McDonald, T. J., Patel, K., Pearson, E. R., Hattersley, A. T., Shields, B. M., & McKinley, T. J. (2024) · BMC Medical Research Methodology · doi:10.1186/s12874-024-02239-w · Cited by 5
Self-citationMaturity-onset diabetes of the young in a large Portuguese cohort
Monteiro, S. S., Santos, T., Fonseca, L., de Assunção, G. V., Lopes, A., Duarte, D. B., Soares, A. R., Laranjeira, F., Ribeiro, I., Pinto, E., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01980-2 · Cited by 4
Metadata
- Authors
- Shields, B. M., Shepherd, M., Hudson, M., McDonald, T. J., Colclough, K., Peters, J., Knight, B., Hyde, C., Ellard, S., Pearson, E. R., & Hattersley, A. T.
- Affiliations
- University of Exeter (GB)
- Royal Devon & Exeter NHS Foundation Trust (GB)
- University of Dundee (GB)
- Corresponding author
- Hattersley, Andrew T.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-07-11
- Volume
- 40
- Issue
- 8
- Pages
- 1017-1025
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC5570522
- OpenAlex
- W2612062408
- Cited by
- 151
- References
- 34
- Citations by year
- 2026: 11 · 2025: 10 · 2024: 14 · 2023: 12 · 2022: 22 · 2021: 19 · 2020: 22 · 2019: 20 · 2018: 20 · 2017: 1
- FWCI
- 11.41
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion, other-oa)
- PubMed Central (acceptedVersion)
- Open Research Exeter (University of Exeter) (acceptedVersion)
- Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (acceptedVersion)
- Figshare (submittedVersion)
- Funders
- Department of Health
- Wellcome Trust (HICF-1009-041, WT-091985)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- monogenic diabetes, young-onset diabetes, biomarker screening, islet autoantibodies, glutamic acid decarboxylase antibodies, maturity-onset diabetes of the young, cystic fibrosis-related diabetes, genetic testing, prevalence, screening pathway
- MeSH terms
- Adult, Autoantibodies, C-Peptide, Creatinine, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, United Kingdom, Humans, Insulin, Male, Middle Aged, Sensitivity and Specificity, Cohort Studies, Biomarkers, Prevalence, Sequence Analysis, DNA, Hepatocyte Nuclear Factor 1-alpha, Hepatocyte Nuclear Factor 4, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.